The administration says it has the ability to employ march-in rights to lower drug prices. When will it actually use them?
NIH
Posted inHealth and Social Policy
Sanders Seeks Investigation of NIH Licensing Practices
The senator wants the inspector general to probe why the NIH licensed a potentially lucrative cancer drug to an obscure company linked to a former employee.
Posted inHealth and Social Policy
The NIH’s ‘How to Become a Billionaire’ Program
An obscure company affiliated with a former NIH employee is offered the exclusive license for a government-funded cancer drug.
Posted inHealth and Social Policy
The Obscure NIH Official Blocking Lower Drug Prices
Mark Rohrbaugh, a mid-level staffer at the National Institutes of Health, has consistently blocked the use of march-in rights to seize patents on high-cost drugs.
Posted inTAP
A Big Miss on Drug Prices
Today on Tap: President Biden’s NIH rejects a petition to seize the patent of an unaffordable prescription drug.
Posted inHealth and Social Policy
Moderna’s COVID Vaccine Price Hike Reveals Government’s Failure
The U.S. co-invented the mRNA vaccine. So why doesn’t it act like it?
Posted inHealth and Social Policy
How a Danish Company Grabbed Control of the Monkeypox Vaccine
German government science and American public money underpinned the development of Jynneos, but one Danish company now controls it entirely.
Posted inHealth and Social Policy
Drug Pricing Reforms Hinge on the Executive Branch
With Congress stuck, the administration holds the key to whether Americans will see meaningful reductions in prescription drug costs. So far, though, they’ve punted.
Posted inHealth and Social Policy
Biden’s Big Chance to Lower Drug Prices
A decision on whether to open a costly cancer drug to generic competition will be made shortly. It doesn’t require congressional approval.
Posted inEnergy and the Environment
Alexandria Ocasio-Cortez and the Myth of American Innovation
The intrepid New Yorker pulls back the curtain on how private companies profit from taxpayer-funded research.